pone.0234539.g006.tif (1.45 MB)
Distinguishing sera of CABG T2DM patients versus controls and CABG patients without T2DM.
figure
posted on 2020-08-05, 18:15 authored by James R. Hocker, Megan Lerner, Stan A. Lightfoot, Marvin D. Peyton, Jess L. Thompson, Subrato Deb, Mathew Reinersman, R. Jane Hanas, Russel G. Postier, Barish H. Edil, Harold M. Burkhart, Jay S. Hanas(A) Sera discrimination of patients with CABG with T2DM (dashes) versus sera from control individuals (squares) by % of LOOCV classified mass peak analysis. (B) Sera discrimination of patients with CABG without T2DM (triangles) versus sera from control individuals (squares). (C) Sera discrimination of CABG patients with T2DM (triangles) from CABG patients without T2DM (squares). (D) Discrimination of the sera samples in the 9 versus 9 grouping of patients with CABG plus T2DM (dashes) versus CABG without T2DM (squares) used in tandem MS/MS peptide/protein analysis exhibited in Table 3 and S1 Table.
